基于水解酶的抗寄生虫前药研究  

Progress on Hydrolases-targeting Antiparasitic Prodrugs

作　　者：温爱丹[1] 张皓冰[1] 

机构地区：[1]中国疾病预防控制中心寄生虫病预防控制所,卫生部寄生虫病原与媒介生物学重点实验室,世界卫生组织疟疾、血吸虫病和丝虫病合作中心,上海200025

出　　处：《中国寄生虫学与寄生虫病杂志》2012年第2期139-145,共7页Chinese Journal of Parasitology and Parasitic Diseases

摘　　要：前药策略已被广泛应用于各种基于药剂学、药代动力学和药效学的药物优化。多数涉及前药转化的酶都属于水解酶,其中以酯水解酶和酰胺水解酶的研究最为广泛。本文综述了基于这两种水解酶的抗寄生虫前药的研究进展。Prodrug strategies have been used for drug optimization to overcome the drawbacks in pharmaceutics,pharmacokinetics and pharmacodynamics.Most enzymes involved in prodrug biotransformation are hydrolases,in which esterase and amidase have been widely researched.This review summarizes the recent progress in antiparasitic prodrugs based on both targets.

关 键 词：前药 水解酶 酯水解酶 酰胺水解酶 抗寄生虫药 

分 类 号：R943.2[医药卫生—药剂学]